Tag: ivosidenib

Home / Established Year

Ivosidenib is approved by FDA for myelodysplastic syndromes
, , , ,

Ivosidenib is approved by FDA for myelodysplastic syndromes

Nov 2023: The Food and Drug Administration (FDA) approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in November 2023 for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) who ..

, , ,

Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia

June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older with..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy